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Autism is the fastest growing developmental disorder in the world today. The prevalence of autism in the US has
risen from 1 in 2500 in 1970 to 1 in 88 children today. People with autism present with repetitive movements and
with social and communication impairments. These impairments can range from mild to profound. The estimated
total lifetime societal cost of caring for one individual with autism is $3.2 million US dollars. With the rapid growth
in this disorder and the great expense of caring for those with autism, it is imperative for both individuals and
society that techniques be developed to model and understand autism. There is increasing evidence that those
individuals diagnosed with autism present with highly diverse set of abnormalities affecting multiple systems of the
body. To this date, little to no work has been done using a whole body systems biology approach to model the
characteristics of this disorder. Identification and modelling of these systems might lead to new and improved
treatment protocols, better diagnosis and treatment of the affected systems, which might lead to improved quality
of life by themselves, and, in addition, might also help the core symptoms of autism due to the potential
interconnections between the brain and nervous system with all these other systems being modeled. This paper
first reviews research which shows that autism impacts many systems in the body, including the metabolic,
mitochondrial, immunological, gastrointestinal and the neurological. These systems interact in complex and highly
interdependent ways. Many of these disturbances have effects in most of the systems of the body. In particular,
clinical evidence exists for increased oxidative stress, inflammation, and immune and mitochondrial dysfunction
which can affect almost every cell in the body. Three promising research areas are discussed, hierarchical, subgroup
analysis and modeling over time. This paper reviews some of the systems disturbed in autism and suggests several
systems biology research areas. Autism poses a rich test bed for systems biology modeling techniques.
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Autism is the fastest rising developmental disorder in
the world today. In the US the rates of autism have risen
from 1 in 2500 in the 1970 [1] to 1 in 88 today [2]. Aut-
ism is defined behaviorally, and is characterized by
impairments in social behavior, stereotypic movements
and difficulties in communicating [3]. Autism presents a
burden upon both families and society as a whole. The
estimated total lifetime societal cost of caring for one in-
dividual with autism is $3.2 million US dollars. This
includes direct costs such as medical, therapeutic, edu-
cational and child and adult care. This figure also
includes indirect costs such as loss of productivity of
both the individual with autism and their caregivers [4].* Correspondence: randolph-gips@uhcl.edu
1Systems Engineering and Computer Engineering, University of Houston – Clear
Lake, 2700 Bay Area Bvd, Houston, TX 77058, USA
Full list of author information is available at the end of the article
© 2012 Randolph-Gips and Srinivasan; licensee
of the Creative Commons Attribution License
distribution, and reproduction in any mediumIn the past autism was considered purely a psycho-
logical [5] or neurological disorder [6]. There is increas-
ing evidence that it is a highly diverse disease affecting
multiple systems of the body. Some systems with strong
evidence of involvement are metabolic, gastrointestinal,
immunological, mitochondrial, and neurological [7,8].
Identification and modeling of these systems may lead to
new treatments. It is hard to predict the all new treat-
ments that would result from a systems approach, but
the first would be better targeting of treatments. At
present, physicians often rely on therapeutic trials and
on psychotropic drugs not approved for autism [9].
One of the difficulties in describing the biology of aut-
ism is that it appears to have multiple etiologies. Some
children have gastrointestinal disease, while others do
not [10]. Some children have frank immune disorders,
while others appear healthy [11]. Some show signs of
autism from birth, while others appear to have a period
of normal development, and then regress [12]. InBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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autism, the complex etiology can be a confounding fac-
tor in many autism studies as the different subgroups
are not apparent using just the defining behavioral
characteristics.
Currently those going in for autism evaluation do not
get a comprehensive workup. These patients cannot ar-
ticulate their problems or have the cognition to request
an evaluation, so we need better lab workups. Many of
these patients present with behavioral challenges, so the
testing procedures should be all-encompassing and as
less invasive as possible. So this whole body approach to
modeling could potentially generate the parameters for a
comprehensive evaluation or intake that would best
guide treatment.
Another difficulty in understanding autism is that the
various systems involved interact in complex and highly
interdependent ways. This complexity points to a new
paradigm in autism research using systems biology. In
addition, autism poses particular difficulties as the scale
of information to be modeled varies widely, from mo-
lecular level to anatomical. The diverse systems involved
in autism and its complex etiology, makes the develop-
ment of new techniques to model autism and mine its
data, imperative. This paper will first review the systems
that are altered in people with autism, and then present
some of the challenges autism presents to system
biologists.
Genetics, metabolism and oxidative stress
Autism has an established genetic component. Studies of
twins shows a concordance of 0-10% in dizygotic twins
and 70-90% in monozygotic twins [13,14]. However, the
search for single autism genes has not been fruitful. It
appears that autism results from a combination of rela-
tively high frequency genes. The current model predicts
that between 10 and 100 possible genetic variants may
be responsible [15]. The rising rates of autism and the
fact that the concordance of identical twins is not 100%
supports the theory that autism results from a combin-
ation of genetic and environmental factors [16-18].
Several genetic variants have been associated with
increased risk for autism. The variants found so far are
mostly associated with differences in the metabolism, ra-
ther than in brain structure. The MET promoter variant
rs1858830 allele “C”, found at increased rates in autism,
is associated with neuronal growth and development,
but also is involved in immune function and gastrointes-
tinal repair [19,20]. The fact that this genetic variant is
present in 47% of the general population gives credence
to the assertion that there is an environmental compo-
nent to the development of autism. Many of the genetic
variants at increased prevalence in autism are associated
with the folic acid, transmethylation and transsulfurationmetabolic pathways. Some of these genes are MTHFR,
COMT, GST, RFC and TCN2. As with the MET variant,
these are common in the general population. These var-
iants decrease the activity of enzymes and decrease the
efficiency of the body’s ability to resolve oxidative stress,
methylate genes and detoxify exogenous and endogen-
ous toxins [21].
Oxidative stress occurs when production of Reactive
Oxygen Species (ROS) and Reactive Nitrogen Species
(RNS) exceeds the body’s ability to neutralize them.
ROS/RNS are free radicals, highly reactive molecules
which can damage many parts of the cell. ROS/RNS
occur through the energy production process in the
mitochondria and through environmental sources. The
mitochondrion is the main source of ROS/RNS and has
evolved a system to neutralize the oxidants. The most
important among these defences is glutathione (GSH). If
the mitochondrial GSH pool is low, increased mitochon-
drial ROS production can occur. GSH is also the main
antioxidant for extra-mitochondrial parts of the cell.
GSH is produced by the sulfuration pathway as shown
in Figure 1. The sulfuration pathway is linked to the
methylation and folic acid pathways and any perturb-
ation of those pathways will affect the production of
GSH.
The methylation pathway provides methyl groups, CH3,
to many functions in the body. S-adenosylmethionine
(SAM) transfers methyl groups to be used in over 150
methyltransferase dependant methylation reactions in the
body [22], most notably the methylation of genes. This
transfer results in S-adenosylhomocysteine (SAH). SAH
can be reversibly transformed into homocysteine and
adenosine by the SAH hydrolase (SAHH). Homocysteine
can then be either remethylated to methionine or can be
transferred to the sulfuration pathway to create glutathi-
one. The pathway flux is influenced by the relative
amounts of the components. If the activity of methionine
synthase (MS) is reduced, either through availability of
its cofactor cobalamin (vitamin B12) or other impair-
ment, less homocysteine will be converted to methionine
to continue the cycle. This will result in more homocyst-
eine and SAH, which reduces SAM dependent methyla-
tion processes. Methylation serves many important
functions in the body. It is used epignetically to turn on
and off genes. A methylated gene will not be expressed
[23]. Methylation is also important in the function of
neurotransmitters, neurohormones, myelin, membrane
phospholids, proteins and creatine [24].
The activity of MS also determines the proportion of
homocysteine shunted into the sulfuration pathway to
make GSH. As the MS cofactor cobalamin is easily oxi-
dized, oxidative stress will cause more homocysteine to
be turned into GSH. In a properly functioning system



















Figure 1 Metabolic pathway diagram of the main cycles in the detoxification pathways. Metabolic products are indicated by ovals and
relevant enzymes by stars. Flux can be either one way, indicated by single arrow lines, or reversible, indicated by double arrow lines.
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stress [25].
Metabolic markers of oxidative stress have been
found to be elevated in children with autism. Gluta-
thione, the main cellular antioxidant, levels were
reduced. In addition, the oxidized disulfide form of
glutathione (GSSG) was increased resulting in a doub-
ling of the GSSG/GSH ratio, The ratio of plasma S-
adenosylmethionine (SAM) to S-adenosylhomocysteine
(SAM/SAH ratio) was reduced [26,27]. Evidence of
increased lipid peroxidation was found which might
indicate oxidative stress [28]. Oxidative stress can have
a negative effect on many systems in the body. It has
been implicated in cancer, cardiovascular disease, and
autoimmune disease [29-31]. Oxidative stress is par-
ticularly destructive to the brain. The brain has higher
energy requirements, high concentration of polyunsat-
urated fatty acids and lower reserves of GSH. Oxida-
tive stress is also increased in schizophrenia, bipolar
disorder and Parkinson’s disease [32-35].
These interacting cycles are of great importance in
autism as they have the potential for therapeutic inter-
vention. Defects in MTHFR enzyme can be bypassed by
supplementing the 5-CH3THF form of folic acid. Sup-
plemental cobalamin can increase the efficiency of MS
[36]. Supplements of other enzyme cofactors might also
be of benefit [7].
The impairment of the metabolic pathways in autism
can result from environmental influences in addition to
genetics. Heavy metals [22] and pesticides [37,38] have
been shown to inhibit the enzymes often deficient in aut-
ism. This could form a feedback loop, where insufficient
activity of these systems allows toxins to remain, where
they can further impair the detoxification systems.Mitochondrial system
Mitochondria are the organelles responsible for the en-
ergy production in most eukaryotic cells. They convert
the energy from carbohydrates and fats into adenosine
triphosphate (ATP) through the process of cellular res-
piration. ATP is used to power most cellular functions.
Mitochondria are also involved in signalling, cellular dif-
ferentiation, and apoptosis, as well as the control of the
cell cycle and cell growth [24].
The mitochondrion utilizes a complex series of chem-
ical reactions to produce the ATP. During this process
free radicals, including the particularly damaging super
oxide, are produced. Since free radicals are so destruc-
tive, the mitochondrion has a series of defences to re-
duce the free radicals. If, due to genetic defects or
acquired dysfunction, more free radicals are produced
than the defences can reduce, oxidative stress can occur
[39]. Mitochondrial disease occurs when there are muta-
tions in the mitochondrial DNA. Mitochondrial disease
is associated with a multitude of disorders including
hypotonia, mitochondrial encephalomyopathy, cardio-
myopathy and a range of endocrine, hepatic or renal
tubular dysfunctions, myoclonic epilepsy and mitochon-
drial myopathy and developmental delay among others.
Mitochondrial disease has many different presentations
as a child can inherit a mixture of normal and mutated
mitochondria from the mother [40].
There is clinical evidence of mitochondrial disease
and dysfunction in autism [41]. Although only a small
minority of people with autism have mitochondrial
DNA (mtDNA) mutations, the rate of autism is higher
among children with mitochondrial disease [42-46]. In
addition, the task of finding genetic mutations influen-
cing mitochondrial function is confounded by the fact
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clear DNA.
Mitochondrial dysfunction occurs when there is
reduced mitochondrial function without genetic changes.
Mitochondrial dysfunction and oxidative stress has been
implicated in a variety of neurodegenerative diseases
such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS) and Hunting-
ton’s disease (HD). Since the brain has high energy
demands, it is more susceptible to damage from faulty
mitochondria [47]. Mitochondria can be inhibited by
many stressors, but chief among them are metals such as
mercury, arsenic, cadmium and lead [48,49]. Pesticides
and industrial chemicals have been found to inhibit mito-
chondrial function [50]. In addition, people with autism
have been found to have higher levels of the bacterium
clostridium in their guts. Clostridium produces proprio-
nic acid, which inhibits the oxidative phosphorylation of
the mitochondria [8].
Although most people with autism have no discernible
mutation indicating primary mitochondrial disorder, lab-
work gives evidence to reduced mitochondrial function,
namely elevated plasma lactate, hyperlactacidemia and
increased lactate/pyruvate ratio. Rarely have mtDNA
changes been found in people with autism with clinical
signs of mitochondrial dysfunction [51-53]. In addition,
levels of enzymes associated with resolving mitochon-
drial produced radical production have been found to be
lower in people with autism [54].
In addition to producing ATP, mitochondria perform
the important function of sequestering calcium. Cal-
cium is also used as a biologic signal between the
mitochondria and the endoplasmic reticulum. Neuronal
calcium signalling causes the release of neurotransmit-
ters and can affect the speed of signals. Diseases with
defects in the mitochondrial calcium pathways have a
high Co-morbid occurrence of autism [55]. Post mor-
tem studies of autistic brains show alterations in cal-
cium homeostasis. This study also showed a possible
connection between ionized calcium levels and the im-
mune system [56].
There are several pathways for impaired mitochondrial
function to affect the brain. The brain has high energy
demands and a limited ability to neutralize free radicals,
thus impaired mitochondria might be damaging to neu-
rons [57]. Mitochondrial dysfunction could also lead to
reduced frequency of neuron firing, particularly of in-
hibitory neurons [58]. Mitochondrial dysfunction could
also affect the brain indirectly, through the immune sys-
tem. Mice with mitochondrial deficiency have reduced
number of immune cells [59], and supplementation of
mitochondrial nutrients improve immune function of
Type 2 diabetic rats [60]. Mitochondrial dysfunction in
areas outside the brain could lead to hepatic productionof VLCFA-containing lipids arising from impaired mito-
chondrial fatty acid beta-oxidation. These lipids can lead
to microglial activation, and release of the neurotoxin
glutamate [61].
Immune system
There is strong evidence of immune dysfunction in chil-
dren with autism. Relatives of children with autism have
increased rates of autoimmune diseases [62]. Imbalances
of immune system cells and cytokines are found in many
different parts of the immune system of people with
autism.
Total levels of lymphocytes are reduced [63,64]. The
serum immunoglobulin subtypes show abnormal pat-
terns. In particular there is often a skewed Th1-Th2
helper ratio, with most people with autism showing a
Th2 predomination [64,65]. T2 skewing results in
increased antibodies which can induce allergies and
autoimmune reactions. Food allergies are common in
children with autism [66]. Th2 skewing also makes
chronic viral infections more likely. Skewing also occurs
in the serum immunoglobulin subtypes. Immunoglobu-
lins are antibodies formed by the B cells to create
humoral, persistant immunity. Immunoglobulins IgM,
IgA, and total IgG are depressed while IgG subtypes
IgG2 and IgG4, and total IgE are increased [67-70].
Increases of pro-inflammatory cytokines along with
reductions of regulatory cytokines have been found [71].
The immune system has the ability to affect the mito-
chondria. Cytokines such as TNFα and IL6 can facilitate
calcium influx and contribute to mitochondrial dysfunc-
tion possibly contributing to the deficits of autism
through the mitochondrial system [72]. Extracellular
mitochondrial DNA and anti-mitochondrial antibodies
have been found in the serum of children with autism
[73].
There are several avenues for the immune system to
induce autistic behaviors. Immune dysregulation could
result in generalized inflammation in the brain [74]. In-
flammation in the brain has been linked to a number of
psychiatric diseases including schizophrenia, [75] bipolar
[76] Alzheimer's disease [77] and depression [78]. Mul-
tiple studies have found a correlation between abnormal
levels of immune factors and core autistic deficits such
as speech, mood and social deficits [79-84]. Another
study found that the more the levels of the cytokines
IL-1, IL5, IL-8 and IL-12p40 deviated from the norm,
the more severe the stereotypical behaviors [85].
Challenge with nasal allergens during the low pollen
winter months resulted in regression in 55% of children
with autism as measured by the Aberrant Behavior
Checklist [86]. Children with autism have been reported
to have fewer aberrant behaviors particularly speech dur-
ing fever as reported in a prospective study [87]. This
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[88].
The interaction between the immune system and the
brain can present in several variations. Neuropeptides
can modulate the immune system by recruitment of the
innate immune system and chemotaxis [11]. In mouse
models, decreased lymphocytes result in impaired learn-
ing and memory [89]. Autoimmunity is present in some
cases. Anti-brain antibodies have been found in children
with autism, though no evidence of demyelination has
been found [11]. A study of 93 children with autism
found that 75% had autoantibodies to the folate recep-
tors in the central nervous system (CNS). Impairments
of these receptors can lead to reduced levels of folate in
the CNS and Cerebral Folate Deficiency (CFD). The
levels of folate receiver antibodies were highly correlated
with cerebrospinal fluid 5-methyltetrahydrofolate con-
centrations, thus indicating possible CFD in the tested
children. There are structural similarities between the
folate receptors and proteins found in milk [90]. A milk
free diet, in addition to high dose folinic acid supple-
mentation has been found to decrease the autoantibody
titer and improve functioning in younger patients
[91,92]. These immunological differences point to treat-
ment options. Replacement of deficient lymphocytes in
mice resolved the learning and memory difficulties [89].
Treatment of allergies often results in improvement in
autistic behaviors such as hyperactivity and irritability
[66]. An early study found that treatment with intraven-
ous immune globulin in ten children with autism
resulted in better speech, eye contact, focus and aware-
ness of surroundings [93].Gastrointestinal system
Incidence of gastrointestinal (GI) disease among those
with autism varies widely, depending on exclusion cri-
teria and whether the study was prospective or retro-
spective. A prospective study showed GI symptoms in
80% of patients with autism [94]. These symptoms in-
clude abdominal pain, chronic diarrhea and or constipa-
tion, and gastro esophageal reflux disease [10]. GI
disease has been confirmed via endoscopy in several
studies [95-97]. Inflammation was found throughout the
GI tract, with reflux esophogitis, stomach inflammation,
duodenum and abnormal carbohydrate digestive enzyme
activity. Other studies have found chronic patchy inflam-
mation and lymphonodular hyperplasia. This is different
than the pattern seen in classical inflammatory bowel
disease, with infiltration of T cells and plasma cells into
the epithelial layers of the mucosa [68,97]. Lymphocyte
infiltration into the epithelial layers of the gut lining and
crypt cells has been found on endoscopy. In addition,
there were IgG antibodies deposited onto the epitheliumand complement immune system activation. This might
be indicative of an autoimmune process [98].
There is evidence of increased intestinal permeability
in people with autism [99-103]. Increased intestinal per-
meability was even found in 43% of children with autism
without clinical signs of bowel dysfunction [101]. Intes-
tinal permeability allows larger molecules that would
normally stay in the gut to cross into the bloodstream.
Plasma and urinary concentrations of oxalate were
greatly elevated in children with autism, which may be a
result of increased intestinal absorption [104]. Increased
permeability can lead to allergy and autoimmune pro-
cesses. There appear to be multiple reasons for the
increased permeability. The dietary protein gluten can
bind to the CXCR3 receptor, resulting in increased
zonulin levels. Zonulin regulates the opening of the tight
junctions in the gut [105]. Ingested toxins such as Poly-
chlorinated Biphenyls can also open the tight junctions
in the gut [106].
Increased incidence of dysbiosis, an imbalance of in-
testinal flora, has been noted in children with autism
[99,107] Dysbiosis can result from use of antibiotics.
As beneficial bacteria are killed, antibiotic resistant
pathogenic organisms can take their place. It has been
theorized that toxins produced by pathogenic organ-
isms may be affecting the brains of individuals with
autism. In addition, decreased levels of disaccharide di-
gestive enzymes have been noted in children with aut-
ism [99].
There are anecdotal reports of improvement of autis-
tic behavior on restricted diets. Some experimental
studies have reported improvements reported include
socialization, speech, strange and unusual behavior
[108,109], stereotyped behaviors, attention/hyperactivity
[110] and physiological symptoms [109] One study of
the casein/gluten free diet considered children with and
without GI symptoms separately. They found greater
improvent in autistic behaviors in children with gastro-
intestinal symptoms compared to those without [109].
The reported improvements may be due to several rea-
sons. Removal of allergens may result in lessened auto-
immune reactions [66]. Removal of gluten may reduce
intestinal permeability [103,105]. Removal of dietary
proteins for which there is insufficient enzymic activity
may reduce dysbiosis [111].
The brain has the potential to directly effect the func-
tioning of the gut. Stress has been implicated in Irritable
Bowel Syndrome with alterations of the intestinal barrier
function, altered balance in enteric microflora, exagger-
ated stress response and visceral hypersensitivity [112].
Antidepressants [113] and therapy [114] have been
found to be effective treatments for irritable bowel syn-
drome (IBS) and inflammatory bowel disease (IBD).
There is also a finding that the brains of patients with
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with controls, though it is unknown whether the brain
changes result from long term IBS or are preexisting
[115].Neurological system
Among the body systems involved in autism is obviously
the brain. Anatomical differences in the cerebellum and
amygdala have been noted in multiple studies, and other
regions have been inconsistently identified as diverging
from the average [116]. Decreases in Purkinje and
granular cells have been noted [117]. Macrocephaly is
present in about 20% of people with autism studied, with
a general upward trend in brain size in other people with
autism. The increase appears to be disproportionately
from white matter enlargement. The cause of the macro-
cephaly is not known, though larger brains are prevalent
among first degree, unaffected relatives. Neuroinflama-
tion is one postulated cause [118].
Minicolumns in the neocortex have been postulated as
the fundamental unit of cognition [119]. Minicolumns in
autistic brains appear to be narrower, with tighter spa-
cing and higher neuron density [120]. Whether this is a
sign of pathology is unclear, as the same variation occurs
in autopsies of three distinguished scientists [121]. Aut-
ism does occur more often in families or mathemati-
cians, engineers and physicists [122]. It has been
theorized that narrow minicolumns facilitate discrimin-
ation and more finely tuned activities, while wider mini-
columns would facilitate generalization. This is
consistent with the behavioral observations of stimulus
overselectivity in autism. Stimulus overselectivity is the
neglect of some features and the overly focused attention
on other features, to the detriment of the observation of
the whole [123]. Evidence also exists for an increased ex-
citatory/inhibitory neuronal activity in the autistic brain
[119,124].
Functional MRI studies are giving evidence to
enhanced local connectivity, and reduced global con-
nectivity in the autistic brain. This might result in an
over analysis of smaller features and an impairment in
synthesizing the information into a coherent whole
[125]. It has been suggested that a feature in the devel-
opment of autistic traits is a low signal to noise ratio in
neural signals. In murine models, constant undifferenti-
ated noise will indefinitely delay the maturation of neu-
rons responsible for processing sound. A similar low
signal to noise ratio in multiple systems in the autistic
brain may be responsible for the impairments observed
[126]. This would be consistent with the underconnec-
tivity theory. Neuronal synchrony may be impaired if
presynaptic and postsynaptic neurons don’t fire within
<100 ms of each other [127].Brain hypoperfusion has been noted in several studies
of subjects with autism. Interestingly, the region affected
can vary widely. Hypoperfusion can result from struc-
tural abnormalities or from global effects such as oxida-
tive stress [7]. Seizures are present in 30% of people with
autism [128]. In addition, subclinical seizures are often
present and treatment with anti-epileptics can result in
mental improvement [129,130].
Modeling autism
All of the systems described above interact in highly
complex ways. To date, little research exists in autism
modeling outside of the genetic and neurological sys-
tems. Finding commonalities between autism and other
conditions may lead to new treatments. Rzhetsky used
statistical models to find genetic overlaps between aut-
ism, bipolar disorder and schizophrenia [131]. Individual
subsystems of importance in autism have been modeled
[132,133], but work needs to be done in modeling com-
binations of systems. It is clear that autism poses a chal-
lenging problem for modeling due to the high level of
interactions between the different elements [134]. The
probably incomplete Figure 2 shows some potential
interactions between the systems discussed in this paper.
For example, an analysis of children with both autism
and mitochondrial disease found that a high proportion,
70%, regressed during a fever [135]. This illustrates just
one example of an intersystem interaction between the
mitochondrial, immune and neurological systems.
The dotted lines in Figure 2 indicate how even the en-
vironment might be effected by the presence of autism.
For example, food allergies or special diets would change
the environment through different food choices. Fecal
incontinence in older children would change the activ-
ities the child would be exposed to. Energy deficits from
mitochondrial dysfunction could affect school activities.
And being oversensitive to sensory input would change
activities and family dynamics.
Much work has been done investigating the genetic
basis of autism. Additional work needs to be done to
find and cluster the genes involved in autism. Modeling
autism will require an integration of both systems and
scales. A few potential research areas are presented
below.
Hierarchical modeling
Modeling autism is complex due to the different physio-
logical scales involved. Issues of importance to model
range from the organ level to the genetic. Most systems
biology to date has emphasized the “lower” levels, with a
strong emphasis on direct genetic interactions. Outside
of a few systems, such as the cardiovascular [136], less
work has been done on an organ scale. To create a true








Figure 2 Proposed interactions between various elements implicated in autism.
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is to use a hierarchical system. Modules can be devel-
oped to model the scale being considered, with appro-
priate links between levels. Techniques have been
borrowed from the systems engineering and software en-
gineering communities to aid and formalize these con-
nections between modules. An example is the BioUML,
an open source platform for multilevel biology modeling
[137]. Hierarchical modeling using rule based models
has been implemented at a cellular level [138].
A hierarchical approach allows for separation of devel-
opment of models for subsystems, but global effects of
different substances and conditions need to be consid-
ered too. Studies of trans-organ and system effects of
substances is a relatively unexplored field of study. For
example, oxidative stress affects the mitochondria dir-
ectly [24], but also the larger systems such as the brain
[47]. Mitochondrial stress may also affect the brain in-
directly. Dysregulation of mitochondrial dynamics has
been implicated in Parkinson’s disease [139]. Mitochon-
drial stress may lead to lipid peroxidation leading to re-
active aldehyde generation in the liver, and finally to
microglial activation and neuronal death [61].
Inflammation can affect many body systems. Inflam-
mation can also be part of a feedback mechanism where
inflammation creates conditions which create or per-
petuate inflammation [140]. Xenobiotic substances must
be taken into account.. Many exogenous substances are
not typically included in existing models. Toxins such as
PCBs, pesticides and heavy metals can affect theefficiency of enzymes often deficient in autism and need
to be considered as a potential causative element
[18,38]. In addition, the effect of toxins in combination
may not be the same as the effect of the toxins in isola-
tion [141-143]. The microbiome, the complex ecosystem
of intestinal flora, may have an impact on many systems
in the body either through immunological effects, or
through the microbial metabolites such as the proprionic
acid produced by clostridium [144]. Special diets and
supplements used by many on the autism spectrum may
affect the composition of the microbiome in addition to
possibly changing the function of enzymes [145,146].Identifying subgroups
In spite of autism’s many common behaviors, it has be-
come evident that autism has a complex etiology and
multiple subgroups. The development of autism appears
to be a complex interaction of genes and environmental
factors. Since most cases of autism are idiopathic, there
are an unknown number of subgroups that may be
present. Treating autism as homogeneous will obscure
the differences required to ascertain the variances
needed for proper treatment. Identification of subgroups
would aid in both research and treatments. As David
Amaral, President of the International Society for Aut-
ism Research states, “There is not going to be rapid pro-
gress in autism research unless we subtype” [147]. This
subtyping can be done on the basis of genes or clinical
data. Clustering has been tried using behavioral
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factors [148-150].
The benefits of subgrouping are as follows. Subgroup-
ing the population might result in subgroups that have
distinctive symptoms and pathology that are already fa-
miliar in the medical literature, and can draw upon
treatments that work in existing treatable conditions.
For example, if one subgroup is a variant of a known
syndrome, we can possibly benefit from the treatments
known in the context of that syndrome. Subtyping
would reduce the use of therapeutic trials, allowing a
more targeted treatment. Another benefit that accrues
from subgrouping is in prevention. If we know the se-
quelae of another similar condition, we can take appro-
priate action to include appropriate preventive measures
in the treatment protocol. For example, if seizures are a
symptom of the similar known syndrome or condition,
potentially a periodic EEG evaluation could be included
in the treatment protocol.
Biomarkers can be used for clustering subgroups.
Many of the metabolic, immunologic, proteomic, genetic
and anatomical differences listed above can be used to
search for subgroups [151,152]. Biomarkers can also be
identified with more advanced methods [16,153]. An im-
portant consideration is that the biomarkers used be
clinically relevant, chosen to maximize the potential for
treatment [154]. For example, the following parameters
could be included in a feature vector in the subgroup
calculation algorithm, for the purpose of clustering:
– Genetics. This can include genetic panels such as
mitochondrial or results of microarray testing.
– Lab test results, such as the above mentioned
metabolic, immunologic and proteomic biomarkers.
– Symptoms and severity as a function of time. These
could be “hard” symptoms such as the presence and
type of epilepsy, or “soft” symptoms such as parent
reports of sociability.
– Treatments and their effectiveness. The treatments
could include steps to address some of the disease
markers discussed above, such as methycobalamin
and folinic acid [36] for methylation issues and
carnitine [61] for mitochondrial issues.
The feature vector would be a vector with both spe-
cific values and binary numbers as markers such as a 1
for the presence of a polymorphism or other hard symp-
tom and a 0 for none. For example, a child with the
MTHFR 677 genotype, a tGSH: GSSG ratio of 8.6 and
no epilepsy could be represented by the feature vector
[1, 8.6, 0]. Once in numerical form, a variety of pattern
recognition techniques can be used.
One popular clustering technique is the K-means
[155]. The k-means algorithm is essentially a densityfinder. It assigns each input vector using an indicator
function to a cluster defined by a prototype vector. The
algorithm then minimizes the global average squared
Euclidean distance from each input vector to the proto-
type. This optimization changes the position of the
prototype vector to reflect Euclidean density patterns.
The prototype center is the average of the input vectors
assigned to it and thus potentially representative of a
subgroup.
One weakness of the k-means is that it performs a
hard assignment of each input vector to a cluster. An in-
put vector is either entirely in a cluster or not at all. This
would not match situations where there might be an
overlap of symptoms. Fuzzy techniques would be of
value in these cases. Fuzzy set theory allows intermediate
levels, between 0 and 1, of belonging to member sets.
The fuzzy c-means (FCM) is a fuzzy generalization of
the k-means algorithm to allow input vectors to belong
to more than one prototype [156]. The FCM also does
not suffer from the stability problems that sometimes
occur in the k-means when an input vector will switch
back and forth between two prototypes, and thus chan-
ging the prototypes in the process.
An important issue with clustering algorithms is the
number and validity of clusters. The k-means and FCM
algorithms will find the number of clusters specified
during program initialization, regardless of the actual
number of clusters. Some clustering algorithms can pro-
duce clusters that are empty or degenerate. Many practi-
tioners will heuristically try different numbers of clusters
and asses the fit. There are also various methods to at-
tempt to quantify the validity of clusters [157]. The Self
Organizing Map (SOM) maintains a proximity relation-
ship between clusters and can be useful for visualization
[158].
The above techniques are unsupervised. Unsupervised
techniques relay wholly on the input data to find clusters
or groupings in the data. Supervised techniques incorp-
orate additional knowledge about the expected group-
ings to guide the cluster development process. This
additional information, if available, can aid in complex
and high dimensional problems. Support Vector
Machines [159,160] and a variety of Neural Network
algorithms can be used to find patterns in the data
[161]. Although supervised algorithms can, in general,
outperform unsupervised algorithms, additional “ground
truth” data is often unavailable. This ground truth can
be information such as genes already associated with a
phenotype or reaction to an intervention. It could also
be symptoms that could also be used as inputs, such as
the before mentioned presence of epilepsy.
Most of the algorithms mentioned above measure
similarity based on the Euclidean distance metric. Eu-
clidean and other Minkowski lp norms such as the “city
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patterns well. Other distance measures are possible such
as various correlation measures [162] and non-spherical
distance measures such as the Mahalanobis distance
[161]. Another issue is the scale of the data. Expected
results in lab tests may vary by several orders of magni-
tude. Therefore, it is usually advisable to normalize the
data before using in an algorithm.
Perhaps the most critical issue is the “Curse of
Dimensionality”. The curse of dimensionality refers to
the somewhat counterintuitive properties of high di-
mensional spaces whereby additional information can
result in a lessening of discernment. The simplest of the
implications of high dimensional space is that the
amount of data required to adequately cover a volume
increases exponentially with dimension. It can be shown
geometrically that most of the volume of a high dimen-
sional Gaussian is contained in its tails, rather than at
its center. This has obvious implications to distance
based algorithms. The distance from a center of a clus-
ter to any point is concentrated in a small interval and
the relative differences from various data points to the
prototype become essentially the same. Thus discrimin-
atory power can decrease with added information, even
if that additional information has discriminatory power
in of itself [163,164]. That has implications for finding
subgroups in a complicated disease such as autism that
might require a large number of features. Feature selec-
tion will alleviate the curse of dimensionality but may
exclude features needed to find less prevalent sub-
groups. The curse of dimensionality may also be avoided
by using subspace methods or hierarchical clustering.
Another issue prevalent in autism data is the abun-
dance of missing data. One cause of missing data would
be different protocols for different studies resulting in
similar but not identical feature vectors. When utilizing
clinical data, physicians will not perform all tests on all
patients, resulting in missing data when patients are
combined. Therefore techniques need to be utilized to
make the most of the data that is present [165,166].
Numerical data in autism research has particular chal-
lenges. The data can refer to disparate body systems.
Data can be problematic to integrate across studies and
research centers. For example, studies can have different
selection criteria, experimental conditions, and goals.
Research centers can have different testing procedures
which can lead to varying results. Data is often not pre-
cise. Fuzzy techniques should be incorporated, as many
of the data considered will not be easily quantifiable,
such as parent reports of behavior. Also, what might be
considered outlier data may in fact be important. It may
be representative of the extreme values that are evident
in autism data [167]. There are a myriad of information
that might be useful in determining autism phenotypes.As mentioned before, it might include items such as
genotype information and lab results. It also might in-
clude items such as parent ratings of diarrhea odor. It is
obvious that a value of ‘1’ in these three categories
would have very different meanings, although numeric-
ally they would be the same.
Incorporating domain knowledge into the identifica-
tion of subgroups will alleviate many of the problems
noted above. As shown in the preceding sections, there
is much qualitative information about autism contained
in the medical literature. Most of it is single system
studies. Techniques need to be discovered to integrate
this information together. One way to incorporate do-
main knowledge is to embed causal information into the
solution [168].
Some preliminary, simple subgrouping has already
shown promise. An analysis of the gluten and casein
elimination diet showed greater improvement in symp-
toms in children with gastrointestinal symptoms com-
pared to those without [109]. This information can help
practitioners decide whether to recommend restrictive
diets. It has been proposed that there may be a mito-
chondrial [58], intestinal permeability [103] and immune
subgroups [11] in autism, but it is probably more com-
plex than that as many children may belong to multiple
subgroups. Thus it is imperative to develop subgroups
that have clinical significance for treating the symptoms
of autism, not just statistical validity.
For example, one could, possibly discover a subtype of
autism that presents with clinical or subclinical seizures
of a certain characteristic type. The treatment of seizures
being a well-studied area, by itself, we could potentially
establish a treatment protocol for patients in this sub-
group, using treatment studies of drugs used for seizures
in these patients also presenting with autism. This would
result in a new treatment for those with autism, in con-
trast to using a seizure medication as an off-label drug
without clear evidence of efficacy in this population.
Time dependent modeling
Another issue of importance is the time scales involved.
Autism is a developmental, not a static disease. Disease
progression might start prenatally and extend through-
out childhood. And of course, the child’s body is
growing and changing. Modeling incorporating time
progression has been primarily on the genetic or cellular
level. Frameworks have been developed for parameter
adjustments during phenotype transitions [169]. Mo-
lecular connectivity maps incorporating differentially
expressed genes have been used to investigate the rela-
tionship of aging to neurological and psychiatric diseases
[170].
Another time range to be considered is the progres-
sion through generations. Transgenerational changes
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bisphenol A exposure during pregnancy in mice resulted
in transgenerational alterations in gene expression and
behavior [171]. Another possible avenue for children
with autism would be that impairments in the mother’s
methylation and sulfur pathways might result in a con-
centration of toxins in a mother. She would then pass
on a greater than normal amount of toxins to her child
prenatally [172] and through breast feeding [173]. This
will impair the detoxification systems of the child from
an early age, resulting in an even greater build-up of tox-
ins. If this child, a girl, has children, she would pass on
an even greater toxic load to her children. As the effects
of toxins are more severe the earlier they are introduced,
this might lead to developmental delays, including aut-
ism. Thus a non-genetic, non-epigenetic trans-gener-
ational inheritance could be occurring. A recent study
showed a three-fold rate increase of autism in the des-
cendants of survivors of the mercury induced Pink dis-
ease (infantile acrodynia). The study did not separate
out matrilineal descendants, so it is impossible to deter-
mine whether there were toxins passed in utero, or
whether the increased incidence was a result of a genetic
hypersensitivity to mercury [174]. This sort of inherit-
ance can also happen in other systems [175]. Induce-
ment of diabetes in pregnant rats will result in increased
prevalence of diabetes and obesity in the offspring. This
can lead to gestational diabetes in the children and per-
petuation of the diabetes through generations, through
environmental causes [176,177].
Another source of time-dependence is that the brain
itself is a state machine, in the sense that future charac-
teristics depend on past characteristics, the various inter-
ventions employed or not employed at a certain time,
etc. Simplified modeling with reasonable assumptions
can be potentially employed to answer questions of gen-
eric value. An example would be “Are outcomes better
for children with regression, who were treated with anti-
epileptic medications prior to puberty, compared to chil-
dren who received such treatment later, after puberty?”
Another example would be “Do children who exhibit
conditions such as gastro-intestinal abnormalities or sei-
zures generally tend to lose these symptoms after a cer-
tain age?” If so, did these children receive a certain
therapy, either medical, educational or behavioral, at a
certain age? In summary, a time-dependent model will
throw more light into brain plasticity and its contribu-
tion to the outcomes that we see in this population.
In order to introduce this complexity, we propose en-
hancing our models using Dynamic Time Warping
(DTW) [178] or a more complex model with state infor-
mation, similar to hidden Markov models where the
body is assumed to be in a state where it produces cer-
tain symptoms or observations and transitions to otherstates based on the model. Estimating these models and
predicting outcomes would be the most complex of the
techniques proposed in this article, and would be the
goal for modeling such a complex time-varying system.
Discussion and conclusions
This paper contains, of necessity, an incomplete review
of the issues involved in autism. Research is exploding in
this area and new findings are being published every
month.
It is clear that the complexity of autism presents a
both challenge and an opportunity for systems biolo-
gists. Modeling autism requires new techniques to be
developed to harness and tame the complexity of inter-
actions. For example, a possible interaction would be
impairment of the detoxification system could allow
toxins to accumulate and cause mitochondrial dysfunc-
tion [48,49], which could cause immune dysfunction
[179,180], which could cause gastrointestinal dysfunc-
tion which could then affect the brain [181]. This is
not to imply that this relation is the cause of autism.
In fact, the whole relation could go the other way, with
stress inducing bowel dysfunction [112]. The bowel
dysfunction could, through opening of tight junctions,
induce immune activation [182], which could contribute
to mitochondrial dysfunction [72], and finally the result-
ant oxidative stress can cause more resources to be used
in the production of GSH, perturbing the metabolic
pathways [183]. And in fact, the chain is not ordered.
Gastrointestinal dysfunction could impair mitochondrial
function directly through the clostridial production of
proprionic acid [8]. These interactions are a purely hypo-
thetical thought experiment and are not to be repre-
sented as causes. But even so, it is apparent that the
number of possible interactions of systems in autism is
almost exponential. This necessitates a system approach.
Autism could be considered a model for other com-
plex diseases. The probable interplay between genetic
and environmental factors is suspected as a factor in
many diseases such as cancer and diabetes. Since many
of the genetic variants that predispose children to autism
are common in the general population, findings in aut-
ism may have much broader implications for the popula-
tion in general.
Autism is the most rapidly increasing developmental
disability with enormous costs to individuals and to soci-
ety. The importance of modeling autism research cannot
be overstated. In summary, the goal of a systems ap-
proach to modeling autism, can potentially lead to the
following concrete benefits. First, having a comprehen-
sive evolving digital data model for autism gives us a
platform to capture the on-going research in an analys-
able format. The model itself can “learn” as results are
incorporated as training data, into the system. Second,
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Follow up questionnaire could result from the system,
based on its knowledge of subtypes and interconnec-
tions, leading to better clinical care for this population.
Third, the system can be used for hypothesis generation,
suggesting possible research topics for clinical trials.
Autism research findings need to be mined, integrated
and modeled to help not just future generations, but also
to improve the outcomes for the current generation of
people with autism.
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